Emerging evidence indicates that the JNK/c-Jun cascade is activated in neurons of the Alzheimer's disease brain and suggests its involvement in abnormal processes, ranging from tau phosphorylation to neuronal death. Substantial new data have accumulated on the functional relevance of causative genes in familial Alzheimer's disease and the pathological processes that occur within neurons. In this review, we summarize reported findings of the JNK/c-Jun cascade in Alzheimer's disease and discuss the relationship between the cascade and other pathological processes. We suggest that the effort to connect amyloid deposition with intracellular activation of the JNK/c-Jun cascade may modify the amyloid theory of Alzheimer's disease. Therapeutic approaches targeting the JNK/c-Jun cascade and other signaling may complement therapeutic strategies directed at reducing amyloid deposition.
Alzheimer A: Uber eine eigenartige Erkrankung der Hirnrinde. Zbl Neurol. Psychiat. 1907; 18: 177-179.
2.
Goate A, Chartier-Harlin MC, Mullan M, et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349: 704-706.
3.
Schellenberg GD, Bird TD, Wijsman ED, et al.: Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992; 258: 668-671.
4.
Scherrington R, Rogaev EI, Liang Y, et al.: Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature. 1995; 375: 754-760.
5.
Levy-Lahad E, Wasco W, Poorkaj P, et al.: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269: 973-977.
6.
Strittmatter WJ, Saunders AM, Schmechel D, et al.: Apolipoprotein E: High-avidity binding to Β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Nat Acad Sci USA. 1993; 90: 1977-1981.
7.
Blacker D, Wilcox MA, Laird NM, et al.: Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 1998; 19: 357-360.
8.
Kang DE, Saito T, Chen X, et al.: Genetic association of the lowdensity lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997; 49: 56-61.
9.
Bertram L, Blacker D, Mullin K, et al.: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 2000; 290: 2302-2303.
10.
Ertekin-Taner N, Graff-Radford N, Younkin LH, et al.: Linkage of plasma AΒ 42 to a quantitative locus on chromosome 10 in lateonset Alzheimer's disease pedigrees. Science. 2000; 290: 2303-2304.
11.
Myers A, Holmans P, Marshall H, et al.: Susceptibility locus for Alzheimer's disease on chromosome 10. Science. 2000; 290: 2304-2305.
12.
Xia W, Zhang J, Perez R, et al.: Interaction between amyloid precursor protein and presenilins in mammalian cells: Implication for the pathogenesis of Alzheimer's disease. Proc Nat Acad Sci USA. 1997; 94: 8208-8213.
13.
Waragai M, Imafuku I, Takeuchi S, et al.: Presenilin-1 binds to amyloid precursor protein directly. Biochem Biophys Res Commun.1997; 239: 480-482.
14.
Weidemann A, Paliga K, Durrwang U, et al.: Formation of stable complexes between two Alzheimer's disease products: Presenilin-2 and beta-amyloid precursor protein. Nature Med.1997; 3: 328-332.
15.
Iwatsubo T, Okada A, Suzuki N, et al.: Visualization of AΒ 42(43) and AΒ 40 in senile plaques with end-specific A monoclonals: Evidence that an initially deposited species is AΒ 42(43). Neuron.1994; 13: 45-53.
Li YM, Lai MT, Xu M, et al.: Presenilin-1 is linked with γ-secretase activity in the detergent solublized state. Proc Nat Acad Sci USA. 2000; 97; 6138-6143.
18.
DeStrooper B, Saftig P, Craessaerts K, et al.: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998; 391: 387-390.
19.
DeStrooper B, Annaert W, Cupers P, et al.: A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature.1999; 398: 518-522.
20.
Wolfe MS, Xia W, Ostaszewski BL, et al.: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 1999; 398: 513-517.
21.
Herreman A, Serneels L, Annaert W, et al.: Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nature Cell Biol.2000; 2: 461-462.
22.
Zhang Z, Nadeau P, Song W, et al.: Presenilins are required for γsecretase cleavage of Β-APPP and transmembrane cleavage of Notch-1. Nature Cell Biol.2000; 2: 463-465.
23.
Li YM, Xu M, Lai MT, et al.: Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin-1. Nature. 2000; 405: 689-694.
Yu G, Nishimura M, Arakawa S, et al.: Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and APP processing. Nature. 2000; 407: 48-54.
26.
Small D: The role of presenilins in γ-secretase activity: catalyst or cofactor?J Neurochem. 2001; 76: 1612-1614.
27.
Cechler F: The multiple paradozes of presenilins. J Neurochem. 2001; 76: 1621-1627.
28.
Capell A, Steiner H, Romig H, et al.: Presenilin-1 differentially facilitates endoproteolysis of the Β-amyloid precursor protein and Notch. Nature Cell Biol.2000; 2: 205-211.
29.
Petit A, Bihel F, daCosta AV, et al.: New protease inhibitors prevent γ-secretase-mediated production of AΒ 40/42 without affecting Notch cleavage. Nature Cell Biol.2001; 3: 507-511.
30.
VanGassen G, Annaert W, VanBroeckhoven C: Binding partners of Alzheimer's disease proteins: Are they physiologically relevant?Neurobiol Dis.2000; 7: 135-151.
31.
Schenk D, Barbour R, Dunn W, et al.: Immunization with amyloid-Β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400: 173-177.
32.
Janus C, Pearson J, McLaurin J, et al.: A peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000; 408: 979-982.
33.
Morgan D, Diamond DM, Gottschall PE, et al.: A vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000; 408: 982-985.
34.
Bard F, Cannon C, Barbour R, et al.: Peripherally administered antibodies against amyloid peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med.2000; 6: 916-919.
35.
Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci.1991; 12: 383-388.
Selkoe DJ: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997; 20: 154-159.
38.
Ishihara T, Hong M, Zhang B, et al.: Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron.1999; 24: 751-762.
39.
Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24: 1121-1159.
40.
Hardy T, Duff K, Hardy J, et al.: Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nature Neurosci. 1998; 1: 355-358.
41.
Ihara Y: PHF and PHF-like fibrils—Cause or consequence?Neurobiol Aging. 2001; 22: 123-126.
42.
Wittmann CW, Wszolek MF, Shulman JM, et al.Tauopathy in drosophila: Neurodegeneration without neurofibrillary tangles. Science. 2001; 293: 711-714.
43.
Klein WL, Krafft GA, Finch CE, et al.: Targeting small A oligomers: The solution to an Alzheimer's conundrum?Trends Neurosci. 2001; 24: 219-224.
44.
Gouras GK, Tsai J, Naslund J, et al.: Intraneural A 42 accumulation in human brain. Am J Pathol.2000; 156: 15-20.
45.
Walsh DM, Tseng BP, Rydel RE, et al.: The oligomerization of amyloid-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000; 39: 10831-10839.
46.
Mochizuki A, Tamaoka A, Shimohata Y, et al.: A 42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. Lancet. 2000; 355: 42-43.
47.
Shoji M, Iwakami N, Takeuchi S, et al.: JNK activation is associated with intracellular-amyloid accumulation. Mol Brain Res.2001; 85: 221-223.
48.
Papolla MA, Omar RA, Kim KS, et al.: Immunological evidence of oxidative stress in Alzheimer's disease. Am J Pathol.1992; 140: 621-628.
49.
Smith MA, Taneda S, Richey PL, et al.: Advanced Maillard reaction products are associated with Alzheimer disease pathology. Proc Nat Acad Sci USA. 1994; 91: 5710-5714.
50.
Vitek MP, Bhattacharya K, Glendening JM, et al.: Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Nat Acad Sci USA. 1994; 91: 4766-4770.
51.
Behl C, Davis JB, Lesley R, et al.: Hydrogen peroxide mediates amyloid protein toxicity. Cell. 1994; 77: 817-827.
52.
Peterson C, Goldman JE: Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Nat Acad Sci USA. 1986; 83: 2758-2762.
53.
Mattson MP, Cheng B, Davis D, et al.: -amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992; 12: 379-389.
54.
Guo Q, Fu W, Sopher BL, et al.: Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Med.1999; 5: 101-106.
55.
Kobayashi S, Ishiguro K, Omori A, et al.: A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtuble. FEBS Lett.1993; 335: 171-175.
56.
Baumann K, Mandelkow EM, Biernat J, et al.: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett.1993; 336: 417-424.
57.
Uchida T, Ishiguro K, Ohnuma J, et al.: Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: Its sequence and developmental change in brain. FEBS Lett.1994; 355: 35-40.
58.
Patrick GN, Zukerberg L, Nikolic M, et al.: Conversion of p35 to p24 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999; 402: 615-622.
59.
Hanger DP, Hughes K, Woodgett JR, et al.: Glycogen synthetase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localization of the kinase. Neurosci Lett.1992; 147: 58-62.
60.
Yang SD, Song JS, Yu JS, et al.: Protein kinase FA/GSK-3 phosphorylates tau on Ser 235-Pro and Ser 404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. J Neurochem. 1993; 61: 1742-1747.
61.
Takashima A, Murayama M, Murayama O, et al.: Presenilin 1 associates with glycogen synthetase kinase 3beta and its substrate tau. Proc Nat Acad Sci USA. 1998; 96: 9637-9641.
62.
Goedert M, Hasegawa M, Jakes R, et al.: Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett.1997; 409: 57-62.
63.
Reynolds CH, Utton MA, Gibb GM, et al.: Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates tau protein. J Neurochem. 1997; 68: 1736-1744.
64.
Goedert M, Hasegawa M, Jakes R, et al.: Phosphorylation of microtuble-associated protein tau by stress-activated protein kinases. FEBS Lett.1997; 409: 57-62.
65.
Zhu X, Raina AK, Rottkamp CA, et al.: Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem. 2001; 76: 435-441.
66.
Kihiko ME, Tucker HM, Rydel RE, et al.: c-Jun contributes to amyloid-induced neuronal apoptosis but is not necessary for amyloid-induced c-jun induction. J Neurochem. 1999; 73: 2609-2612.
67.
Anderson AJ, Cumming BJ, Cotman CW: Increased immunoreactivity for Jun-and Fos-related proteins in Alzheimer's disease: Association with pathology. Exp Neurol.1994; 126: 286-295.
68.
MacGibbon GA, Lawlor PA, Walton M, et al.: Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. Exp Neurol.1995; 147: 316-332.
69.
Marcus DL, Strafaci JA, Miller DC, et al.: Quantitative neuronal c-fos and c-jun expression in Alzheimer's disease. Neurobiol Aging. 1998; 5: 393-400.
70.
Imafuku I, Masaki T, Waragai M, et al.: Presenilin-1 suppresses the function of c-jun homodimers via intgeraction with QM/Jif-1. J Cell Biol.1999; 147: 121-133.
71.
Kim JW, Chang T-S, Lee JE, et al.: Negative regulation of SAPK/JNK signaling pathway by presenilin 1. J Cell Biol.2001; 153: 457-463.
72.
Katayama T, Imaizumi K, Sato N, et al.: Presenilin-1 mutations down-regulate the signalling pathway of the unfolded-protein response. Nature Cell Biol.1999; 8: 479-485.
73.
Niwa M, Sidrauski C, Kaufman RJ, et al.: A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. Cell. 1999; 99: 691-702.
74.
Sato N, Urano F, Yoon Leem J, et al.: Up-regulation of BiP and CHOP by the unfolded protein response is independent of presenilin expression. Nature Cell Biol.2000; 12: 863-870.
75.
Imaizumi K, Katayama T, Tohyama M: Presenilin and the UPR. Nature Cell Biol.2001; 3: E104-E104.
76.
Urano F, Wang X, Bertolotti A, et al.: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRS1. Science. 2000; 287: 664-666.
77.
Kovacs DM, Wasco W, Witherby J, et al.: The upstream stimulatory factor functionally interacts with the Alzheimer amyloid-protein precursor gene. Hum Mol Genet. 1995; 4: 1527-1533.
78.
Oppenheim RW: Cell death during development of the nervous system. Ann Rev Neurosci. 1991; 14: 453-501.
79.
Gorin PD, Johnson EM, Jr.: Effects of long-term nerve growth factor deprivation on the nervous system of the adult rat: an experimental approach. Brain Res.1980; 198: 27-42.
80.
Deckwerth TL, Johnson EM, Jr.: Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor (NGF). J Cell Biol.1993; 123: 1207-1222.
81.
Edwards SN, Tolkovsky AM: Characterization of apoptosis in cultured rat sympathetic neurons after nerve growth factor withdrawal. J Cell Biol.1994; 124: 537-546.
82.
Martin DP, Schmidt RE, Distefano PS, et al.: Inhibitors of protein synthesis and RNA synthesis prevent neuronal death caused by nerve growth factor deprivation. J Cell Biol.1988; 106: 829-844.
83.
Greenlund LJS, Deckwerth TL, Johnson EM, Jr.: Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death of protects sympathetic neurons from NGF deprivation induced apoptosis. Neuron.1995; 14: 303-315.
84.
Jordan J, Ghadge GD, Prehn JH, et al.: Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth factor. Mol Pharmacol. 1995; 47: 1095-1100.
85.
Estus S, Zaks W, Freeman R, et al.: Altered gene expression in neurons during programmed cell death: Identification of c-Jun as necessary for neuronal apoptosis. J Cell Biol.1994; 127: 1717-1727.
86.
Ham J, Babij C, Whitfield J, et al.: A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron.1995; 14: 927-939.
87.
Deshmukh D, Vasilakos J, Deckwerth TL, et al.: Genetic and metabolic status of NGF-deprived sympathetic neurons saved by an inhibitor of ICE-family protease. J Cell Biol.1997; 135: 1341-1354.
88.
Deshmukh M, Kuida K, Johnson EM, Jr.: Caspase inhibition extends the commitment to neuronal death beyond cytochrome c release to the point of mitochondrial depolarization. J Cell Biol.2000; 150: 131-143.
89.
Putcha GV, Deshmukh M, Johnson EM, Jr.: Inhibition of apoptotic signaling cascades causes loss of trophic factor dependence during neuronal maturation. J Cell Biol.2000; 149: 1011-1018.
90.
Eilers A., Whitfield J, Babij C, et al.: Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons. J Neurosci. 1998; 18: 1713-1724.
91.
Eilers A., Whitfield J, Shah B, et al.: Direct inhibition of c-Jun Nterminal kinase in sympathetic neurones prevents c-Jun promoter activation and NGF withdrawal-induced death. J Neurochem. 2001; 76: 1439-1454.
92.
Tammariello SP, Landreth GE, Estus S: The role of Jun-kinases in apoptosis. In Mattson MP, Estus S, Rangnekar V (eds.): Programmed Cell Death: Cellular and Molecular Mechanisms. New York: Humana Press, 2001: 197-214.
93.
Xia Z, Dickens M, Raingeaud J, et al.: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995; 270: 1326-1331.
94.
Maroney AC, Finn JP, Bozyczko-Coyne D, et al.: CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem. 1999; 73: 1901-1912.
95.
Bruckner SR, Tammariello SP, Kuan CY, et al.: JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J Neurochem. 2001; 78: 298-303.
96.
Behrens A, Sibilia M, Wagner EF: Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nature Genet.1999; 21: 326-329.
97.
Putcha GV, Moulder KL, Golden JP, et al.: Induction of BIM, a proapoptotic BH3-only Bcl-2 family member, is critical for neuronal apoptosis. Neuron.2001; 29: 615-628.
98.
Whitfield J, Neame SJ, Paquet L, et al.: Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron.2001; 29: 629-643.
99.
Harris CA, Johnson EM, Jr.: BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem.2001; 8 [published on line].
100.
Deshmukh M and Johnson EM, Jr.: Evidence of a novel event during neuronal death: Development of competence-to-die in response to cytoplasmic cytochrome C. Neuron.1998; 21: 695-705.
101.
Forloni G, Chiesa R, Smiroldo S, et al.: Apoptosis mediated neurotoxicity induced by chronic application of-amyloid fragment 25-35. Neuroreport. 1993; 4: 523-526.
102.
Loo DT, Copani A, Pike CJ, et al.: Apoptosis is induced by AΒ-amyloid in cultured central nervous system neurons. Proc Nat Acad Sci USA. 1993; 90: 7951-7955.
103.
Watt JA, Pike CJ, Walencewicz-Wasserman AJ, et al.: Ultrastructural analysis of beta-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res.1994; 661: 147-156.
104.
Estus S, Tucker HM, Van Rooyen C, et al.: Aggregated amyloid-Β protein induces cortical neuronal apoptosis and concomitant apoptotic pattern of gene induction. J Neurosci. 1997; 17: 7736-7745.
105.
Pike C, Walencewicz A, Glabe C, et al.: In vitro aging of Β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res.1991; 563: 311-314.
106.
Simmons LK, May PC, Tomaselli KJ, et al.: Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994; 45: 373-379.
107.
Anderson AJ, Pike CJ, Cotman CW: Differential induction of immediate early gene proteins in cultured neurons by Β-amyloid (AΒ): Association of c-Jun with AΒ induced apoptosis. J Neurochem. 1995; 65: 1487-1498.
108.
Troy CM, Rabacchi SA, Xu Z, et al.: Β-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 2001; 77: 157-164.
109.
Yang DD, Kuan CY, Whitmarsh AJ, et al.: Absence of excitotoxicityinduced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 1997; 389: 865-870.
110.
Lewis J, Dickson DW, Lin WL, et al.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001; 293: 1487-1491.
111.
Irizarry MC, McNamara M, Fedorchak K, et al.: APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol.1997; 56: 965-973.
112.
Cherny RA, Atwood CS, Xilinas ME, et al.: Treatment with a copper-zinc chelator markedly and rapidly inhibitsamyloid accumulation in Alzheimer's disease transgenic mice. Neuron.2001; 30: 665-676.
113.
Bozyczko-Coyne D, O'Kane TM, Wu Z-L, et al.: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Ainduced cortical neuron apoptosis. J Neurochem. 2001; 77: 849-863.
114.
Cross DAE, Culbert AA, Chalmers KA, et al.: Selective smallmolecule inhibitors of glycogen synthetase kinase-3 activity protect neurones from death. J Neurochem. 2001; 77: 94-102.
